admin

Assessment of Therapeutic Tumor Response Using 99mTc-Ethylenedicysteine-Glucosamine.

http://www.cellpointweb.com/pdf/EC%20Glucosamine%20Nov%202004.pdf

Tumor Specific Imaging Using Tc-99m and Ga-68 Labeled Radiopharmaceuticals.

http://www.cellpointweb.com/pdf/EC%20GA%2068%20Jan%202005.pdf

Cell>Point to Present at the 26th Indian Cooperative Oncology Network (ICON) Meeting in Bengaluru, India

CENTENNIAL, Colo., March 17, 2012 – Cell>Point today that Company President David Rollo, M.D., Ph.D.,will present at the 26th Indian Oncology Network (ICON) Meeting in Bengaluru, India, On Saturday, March 27, 2012, at 10:45 a.m. local time. The ICON meeting will be held at the Crowne Plaza in Bengaluru.

http://www.cellpointweb.com/Press-Release-EC-G%20Cardio-1b-2-IND-Final.pdf

Cell>Point Announces Agreement with the FDA on a Special Protocol Assessment for the Phase 3 Technetium-99m-EC-G Lung Cancer Imaging Trial

CENTENNIAL, Colo., March 8, 2012 – Cell>Point, L.L.C , announced today that it received a letter from the U.S. Food and Drug Administration (FDA) indicating that agreement has been reached pursuant to a Special Protocol Assessment regarding the design of its Phase 3 pivotal clinical study in lung cancer.

http://www.cellpointweb.com/spa-press-release-march-8-2012.pdf

Cell>Point Executes Asia License with HYUN IMC for Cancer and Heart Disease Diagnostic Imaging Agent, Technetium99mEC-G

CENTENNIAL, Colo., February 28, 2012 – Cell>Point announced today that it had entered into a licensing agreement for countries of the South Korea, Taiwan, Malaysia, Vietnam, and the Philippines with HYUN IMC Co.,Ltd., headquatered in Seoul, South Korea.

http://www.cellpointweb.com/PR-Feb-28-2012.pdf

CENTENNIAL, Colo., January 24, 2012—Cell>Point announced today that it has entered into a long-term collaboration agreement including product licenses for Brazil with MJM Productos Farmaceuticos e de Radioprotecao Ltda., or “Radiopharmacus.”

Cell>Point announced today that it has entered into a long-term collaboration agreement including product licenses for Brazil with MJM Productos Farmaceuticos e de Radioprotecao Ltda., or “Radiopharmacus.”
The agreement leads with Cell>Point’s cancer and cardiology molecular imaging agent—EC-G or, specifically, 99mTc-EC-G (99mTechnetium-EthylenediCysteine-n-acetyl-Glucosamine)—but covers the entire portfolio of products being developed by Cell>Point. EC-G has completed a U.S. Phase 2 clinical trial for non-small cell lung cancer diagnosis and staging, and a Phase 1 trial for coronary artery disease diagnosis.In addition to the exclusive right to manufacture and sell Cell>Point products in Brazil following regulatory approval, Radiopharmacus will also provide a range of services including commercial scale synthesis, cGMP (certified Good Manufacturing Practice) manufacturing, preclinical studies, clinical studies, and regulatory interface.
“We are very pleased to have a strategic partner in Brazil like Radiopharmacus,” said Greg Colip, Cell>Point chief executive officer.
“The broad scope of the relationship shouldhelp shorten the lead time to complete the chemistry, manufacturing and control process for each of our products, and allow us to explore the clinical feasibility of each product before ramping up clinical-development investment.”
Regarded as one of the most promising and attractive pharmaceutical markets in the Americas, the Brazilian market is the 11th largest globally at $17 billion dollars in annual sales, per Business Monitor International 2010 data. The Brazilian pharmaceutical market also has had consistently high growth over the last decade.
Radiopharmacus will manufacture EC-G product “kits” for Brazilian clinical studies and for sale in Brazil, following marketing approval by ANVISA, Brazil’s National Health Surveillance Agency.Radiopharmacus is affiliated with a leading Brazilian Contract Research Organization (CRO), which will oversee clinical trials conducted in Brazil.

CENTENNIAL, Colo., November 23, 2011

Cell>Point announced today that the University of Texas M.D. Anderson Cancer Center will present pre-clinical results on Cell>Point’s therapeutic, Platinum-EC-G, for Aggressive type-B Lymphoma at the 53rd American Society of Hematology Annual Meeting December 10-13, 2011

CENTENNIAL, Colo., June 6, 2011—Cell>Point announced today that it will present Phase 2 clinical trial results for its cancer molecular imaging agent, 99mTc-EC-G

http://www.cellpointweb.com/2011-SNM-Final.pdf

CENTENNIAL, Colo., March 18, 2010—Cell>Point announced today that it was awarded March 15, 2011 the North American SPECT Radiopharmaceuticals Technology Innovation Award by Frost & Sullivan.

Embed Video

Cell>Point adds Dr. Wayne Yakes to Board of Advisors – 11/22/2010

CENTENNIAL, Colo., November 22, 2010 – Cell>Point is pleased to announce that Dr. Wayne Yakes has joined our Board of Advisors.  Dr. Yakes currently serves as the Director of the Vascular Malformation Center, Interventional Neuroradiology and Interventional Radiology – Swedish Medical Center, Englewood, Colorado.  Dr. Yakes is board certified in Radiology, Interventional Radiology and Neuroradiology with thirty one clinical professor appointments with university medical centers around the world including the University of Michigan Medical School, University of London Medical Center and Royal St. Albert’s University Medical Center.  Forty eight medical publications have been authored or co-authored by Dr. Yakes in addition to five hundred and eighty five medical presentations.  Dr. Yakes is a 1975 Distinguished Military Graduate and selected by Department of Army for the Military Intelligence Corps.  Dr. Yakes received both his Airborne Paratrooper Badge and Ranger Tab in 1974.  Dr. Yakes received his B.A. from Rice University in 1975 and M.D. from Creighton University School of Medicine in 1979.

Cell>Point to present at 52nd American Society of Hematology Annual Meeting December 4-7, 2010.

CENTENNIAL, Colo., December 1, 2010 – Dr. Lan V. Pham, Department of Hematophathology, The University of Texas M.D. Anderson Cancer Center, will be presenting the following paper titled “Metabolic Targeted Therapy for Aggressive B-cell Lymphomas: Evaluating Glucose Metabolism and the Potential of 187Rhenium-Ethylenedicysteine – N- AcetylGlucosamine (187Re-EC-G) for Therapy” at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida. 187Re-ECG utilizes Cell>Point’s intra-nuclear targeting technology EC-G.  The company successfully targeted lymphoma with EC-G in its Phase 1 99mTc-EC-G imaging trial conducted several years ago.  By substituting 99mTc with 187Re, the targeted diagnostic imaging agent is converted into a target specific therapeutic agent.  Key findings of the presentation show that 187Re-EC-G enters the nucleus and impacts the DNA which leads to lymphoma cell apoptosis.  An additional finding suggests that 187Re-Ec-G is an excellent potential candidate for targeted therapy in aggressive r/r lymphomas.

CENTENNIAL, Colo., March 18, 2010

Cell>Point announced today that it was awarded March 15, 2011 the North American SPECT Radiopharmaceuticals Technology Innovation Award by Frost & Sullivan.

CENTENNIAL, Colo., June 21, 2010

Cell>Point announced today that it has submitted to the US Food and Drug Administration (FDA) an Investigational New Drug (IND) application for a Phase 1b/2 trial of its 99mTc‐EC‐G diagnostic in assessing patients with Coronary Artery Disease (CAD).

CENTENNIAL, Colo., June 3, 2010

Cell>Point announced today that it will present clinical results for its cancer imaging agent, 99mTc-EC-G, used to assess the efficacy of chemotherapy at the 2010 Society of Nuclear Medicine Annual Meeting on June 7, 2010.

CENTENNIAL, Colo., February 10, 2010

Cell>Point announced today that M. Donald Blaufox, M.D., Ph.D, will be coordinating principal investigator for its Phase 2/3 clinical trial of99mTc-EC-G for cancer diagnostic imaging. The trial is currently underway.